An overview of monitoring and supplementation of omega 3 fatty acids in cystic fibrosis

Clinical Biochemistry

Volumn 40, Issue 8, 2007, Pages 511-520

  Coste, Thierry Charles ^a   Armand, Martine ^b   Lebacq, Jean ^a   Lebecque, Patrick ^a   Wallemacq, Pierre ^a   Leal, Teresinha ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b INSERM   (France)

Author keywords

3; Cystic fibrosis; Docosahexaenoic acid; Essential fatty acids; Monitoring

Indexed keywords

ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; DOCOSAPENTAENOIC ACID; ESSENTIAL FATTY ACID; GAMMA LINOLENIC ACID; ICOSAPENTAENOIC ACID; ICOSATETRAENOIC ACID; LINOLEIC ACID; LINOLENIC ACID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PHOSPHOLIPID; PLACEBO; POLYUNSATURATED FATTY ACID; STEARIDONIC ACID;

ABDOMINAL CRAMP; ABDOMINAL PAIN; CLINICAL TRIAL; CYSTIC FIBROSIS; DIET SUPPLEMENTATION; DIETARY INTAKE; DRUG EFFECT; ERYTHROCYTE MEMBRANE; ESSENTIAL FATTY ACID DEFICIENCY; FAT INTAKE; FATTY ACID ANALYSIS; FATTY ACID BLOOD LEVEL; FATTY ACID METABOLISM; HUMAN; LIPID COMPOSITION; NAUSEA; NONHUMAN; NUTRITION; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; STEATORRHEA; TISSUE LEVEL; TREATMENT DURATION; TREATMENT OUTCOME;

CYSTIC FIBROSIS; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; DRUG MONITORING; FATTY ACIDS, OMEGA-3; FATTY ACIDS, UNSATURATED; HUMANS; MODELS, BIOLOGICAL;

EID: 34247169193     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2007.01.002     Document Type: Review

References (86)

1. Kerem B., Rommens J.M., Buchanan J.A., et al. Identification of the cystic fibrosis gene: genetic analysis. Science 245 (1989) 1073-1080
2. Riordan J.R., Rommens J.M., Kerem B., et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245 (1989) 1066-1073
3. Sinaasappel M., Stern M., Littlewood J., et al. Nutrition in patients with cystic fibrosis: a European consensus. J. Cyst. Fibros 1 (2002) 51-75
4. Lukacs G.L., Mohamed A., Kartner N., Chang X.B., Riordan J.R., and Grinstein S. Conformational maturation of CFTR but not its mutant counterpart (delta F508) occurs in the endoplasmic reticulum and requires ATP. EMBO J. 13 (1994) 6076-6086
5. Zentler-Munro P.L., Fine D.R., Batten J.C., and Northfield T.C. Effect of cimetidine on enzyme inactivation, bile acid precipitation, and lipid solubilisation in pancreatic steatorrhoea due to cystic fibrosis. Gut 26 (1985) 892-901
6. Regan P.T., Malagelada J.R., DiMagno E.P., and Go V.L. Reduced intraluminal bile acid concentrations and fat maldigestion in pancreatic insufficiency: correction by treatment. Gastroenterology 77 (1979) 285-289
7. Carroccio A., Pardo F., Montaldo G., et al. Use of famotidine in severe exocrine pancreatic insufficiency with persistent maldigestion on enzymatic replacement therapy. A long-term study in cystic fibrosis. Dig. Dis. Sci. 37 (1992) 1441-1446
8. Steinkamp G., and Wiedemann B. Relationship between nutritional status and lung function in cystic fibrosis: cross sectional and longitudinal analyses from the German CF quality assurance (CFQA) project. Thorax 57 (2002) 596-601
9. Christophe A., and Robberecht E. Current knowledge on fatty acids in cystic fibrosis. Prostaglandins Leukot. Essent Fatty Acids 55 (1996) 129-138
10. Burr G.O., and Burr M.M. On the nature and role of fatty acids essential in nutrition. J. Biol. Chem. 86 (1930) 587-621
11. Burr G.O., and Burr M.M. Deficiency disease, produced by the rigid exclusion of fat from the diet. J. Biol. Chem. 82 (1929) 345-367
12. Paulsrud J.R., Pensler L., Whitten C.F., Stewart S., and Holman R.T. Essential fatty acid deficiency in infants induced by fat-free intravenous feeding. Am. J. Clin. Nutr. 25 (1972) 897-904
13. Richardson T.J., and Sgoutas D. Essential fatty acid deficiency in four adult patients during total parenteral nutrition. Am. J. Clin. Nutr. 28 (1975) 258-263
14. Lauritzen L., Hansen H.S., Jorgensen M.H., and Michaelsen K.F. The essentiality of long chain n-3 fatty acids in relation to development and function of the brain and retina. Prog. Lipid Res. 40 (2001) 1-94
15. Dijck-Brouwer D.A., Hadders-Algra M., Bouwstra H., et al. Lower fetal status of docosahexaenoic acid, arachidonic acid and essential fatty acids is associated with less favorable neonatal neurological condition. Prostaglandins Leukot. Essent Fatty Acids 72 (2005) 21-28
16. Simopoulos A.P. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed. Pharmacother. 56 (2002) 365-379
17. Zamaria N. Alteration of polyunsaturated fatty acid status and metabolism in health and disease. Reprod. Nutr. Dev. 44 (2004) 273-282
18. Das U.N. Essential fatty acids: biochemistry, physiology and pathology. Biotechnol. J. 1 (2006) 420-439
19. Serhan C.N., Arita M., Hong S., and Gotlinger K. Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers. Lipids 39 (2004) 1125-1132
20. Desvergne B., and Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 20 (1999) 649-688
21. Berger J., and Moller D.E. The mechanisms of action of PPARs. Annu. Rev. Med. 53 (2002) 409-435
22. Coste T.C., Gerbi A., Vague P., Maixent J.M., Pieroni G., and Raccah D. Peripheral diabetic neuropathy and polyunsaturated fatty acid supplementations: natural sources or biotechnological needs?. Cell Mol. Biol. 50 (2004) 845-853
23. Kuo P.T., Huang N.N., and Bassett D.R. The fatty acid composition of the serum chylomicrons and adipose tissue of children with cystic fibrosis of the pancreas. J. Pediatr. 60 (1962) 394-403
24. Kuo P.T., and Huang N.N. The effect of medium chain triglyceride upon fat absorption and plasma lipid and depot fat of children with cystic fibrosis of the pancreas. J. Clin. Invest. 44 (1965) 1924-1933
25. Caren R., and Corbo L. Plasma fatty acids in pancreatic cystic fibrosis and liver disease. J. Clin. Endocrinol. Metab. 26 (1966) 470-477
26. Bennett M.J., Medwadowski B.F., and Vitamin A. vitamin E, and lipids in serum of children with cystic fibrosis or congenital heart defects compared with normal children. Am. J. Clin. Nutr. 20 (1967) 415-421
27. Underwood B.A., Denning C.R., and Navab M. Polyunsaturated fatty acids and tocopherol levels in patients with cystic fibrosis. Ann. N. Y. Acad. Sci. 203 (1972) 237-247
28. Rosenlund M.L., Kim H.K., and Kritchevsky D. Essential fatty acids in cystic fibrosis. Nature 251 (1974) 719
29. McEvoy F.A. Essential fatty acids and cystic fibrosis. Lancet 306 (1975) 236
30. Farrell P.M., Bieri J.G., Fratantoni J.F., Wood R.E., and di Sant'Agnese P.A. The occurrence and effects of human vitamin E deficiency. A study in patients with cystic fibrosis. J. Clin. Invest. 60 (1977) 233-241
31. Hubbard V.S., Dunn G.D., and Di Sant'Agnese P.A. Abnormal fatty-acid composition of plasma-lipids in cystic fibrosis. A primary or a secondary defect?. Lancet 310 (1977) 1302-1304
32. Chase H.P., and Dupont J. Abnormal levels of prostaglandins and fatty acids in blood of children with cystic fibrosis. Lancet 312 (1978) 236-238
33. Kutty K.M., Guha A.K., Chandra R.K., and Vaze D. A study of erythrocyte fatty acids, adenosinetriphosphatase and acetylcholinesterase in cystic fibrosis. Clin. Biochem. 12 (1979) 98-99
34. Hubbard V.S., and Dunn G.D. Fatty acid composition of erythrocyte phospholipids from patients with cystic fibrosis. Clin. Chim. Acta 102 (1980) 115-118
35. Rogiers V., Crokaert R., and Vis H.L. Altered phospholipid composition and changed fatty acid pattern of the various phospholipids fractions of red cell membranes of cystic fibrosis children with pancreatic insufficiency. Clin. Chim. Acta 105 (1980) 105-115
36. Rogiers V., Dab I., Crokaert R., and Vis H.L. Long chain non-esterified fatty acid pattern in plasma of cystic fibrosis patients and their parents. Pediatr. Res. 14 (1980) 1088-1091
37. Hubbard V.S., Dunn G.D., and Lester L.A. Effectiveness of cimetidine as an adjunct to supplemental pancreatic enzymes in patients with cystic fibrosis. Am. J. Clin. Nutr. 33 (1980) 2281-2286
38. Lloyd-Still J.D., Johnson S.B., and Holman R.T. Essential fatty acid status in cystic fibrosis and the effects of safflower oil supplementation. Am. J. Clin. Nutr. 34 (1981) 1-7
39. Rogiers V., Vercruysse A., Dab I., and Baran D. Abnormal fatty acid pattern of the plasma cholesterol ester fraction in cystic fibrosis patients with and without pancreatic insufficiency. Eur. J. Pediatr. 141 (1983) 39-42
40. Rogiers V., Dab I., Michotte Y., Vercruysse A., Crokaert R., and Vis H.L. Abnormal fatty acid turnover in the phospholipids of the red blood cell membranes of the cystic fibrosis patients (in vitro study). Pediatr. Res. 18 (1984) 704-709
41. Farrell P.M., Mischler E.H., Engle M.J., Brown J., and Lau S.M. Fatty acid abnormalities in cystic fibrosis. Pediatr. Res. 19 (1985) 104-109
42. Gibson R.A., Teubner J.K., Haines K., Cooper D.M., and Davidson G.P. Relationship between pulmonary function and plasma fatty acid levels in cystic fibrosis patients. J. Pediatr. Gastroenterol. Nutr. 5 (1986) 408-415
43. Biggemann B., Laryea M.D., Schuster A., Griese M., Reinhardt D., and Bremer H.J. Status of plasma and erythrocyte fatty acids and vitamin A and E in young children with cystic fibrosis. Scand. J. Gastroenterol. 23 (1988) 135-141
44. Parsons H.G., O'Loughlin E.V., Forbes D., Cooper D., and Gall D.G. Supplemental calories improve essential fatty acid deficiency in cystic fibrosis patients. Pediatr. Res. 24 (1988) 353-356
45. Thompson G.N. Relationship between essential fatty acid levels, pulmonary function and fat absorption in pre-adolescent cystic fibrosis children with good clinical scores. Eur. J. Pediatr. 148 (1989) 327-329
46. Lepage G., Levy E., Ronco N., Smith L., Galeano N., and Roy C.C. Direct transesterification of plasma fatty acids for the diagnosis of essential fatty acid deficiency in cystic fibrosis. J. Lipid Res. 30 (1989) 1483-1490
47. Llyod-Still J.D., Johnson S.B., and Holman R.T. Essential fatty acid status and fluidity of plasma phospholipids in cystic fibrosis infants. Am. J. Clin. Nutr. 54 (1991) 1029-1035
48. Christophe A., Robberecht E., De Baets F., and Franckx H. Increase of long chain omega-3 fatty acids in the major serum lipid classes of patients with cystic fibrosis. Ann. Nutr. Metab. 36 (1992) 304-312
49. Christophe A., Robberecht E., Franckx H., De Baets F., and van de Pas M. Effect of administration of gamma-linolenic acid on the fatty acid composition of serum phospholipids and cholesteryl esters in patients with cystic fibrosis. Ann. Nutr. Metab. 38 (1994) 40-47
50. Christophe A.B., Warwick W.J., and Holman R.T. Serum fatty acid profiles in cystic fibrosis patients and their parents. Lipids 29 (1994) 569-575
51. Lloyd-Still J.D., Bibus D.M., Powers C.A., Johnson S.B., and Holman R.T. Essential fatty acid deficiency and predisposition to lung disease in cystic fibrosis. Acta Paediatr. 85 (1996) 1426-1432
52. Roulet M., Frascarolo P., Rappaz I., and Pilet M. Essential fatty acid deficiency in well nourished young cystic fibrosis patients. Eur. J. Pediatr. 156 (1997) 952-956
53. Steinkamp G., Demmelmair H., Ruhl-Bagheri I., von der Hardt H., and Koletzko B. Energy supplements rich in linoleic acid improve body weight and essential fatty acid status of cystic fibrosis patients. J. Pediatr. Gastroenterol. Nutr. 31 (2000) 418-423
54. Strandvik B., Gronowitz E., Enlund F., Martinsson T., and Wahlstrom J. Essential fatty acid deficiency in relation to genotype in patients with cystic fibrosis. J. Pediatr. 138 (2001) 650-655
55. Lepage G., Yesair D.W., Ronco N., et al. Effect of an organized lipid matrix on lipid absorption and clinical outcomes in patients with cystic fibrosis. J. Pediatr. 141 (2002) 178-185
56. Innis S.M., Davidson G.F., Chen A., Dyer R., Melnyk S., and James S.J. Increased plasma homocysteine and S-adenosylhomocysteine and decreased methionine is associated with altered phosphatidylcholine and phosphatidylethanolamine in cystic fibrosis. J. Pediatr. 143 (2003) 351-356
57. Walkowiak J., Wilczynski M., Boleslawska I., Krawczynski M., Korzon M., and Przyslawski J. The predominance of omega-6 polyunsaturated fatty acids in cystic fibrosis despite low arachidonic acid levels. Acta Paediatr. 92 (2003) 1354-1355
58. De Vizia B., Raia V., Spano C., Pavlidis C., Coruzzo A., and Alessio M. Effect of an 8-month treatment with omega-3 fatty acids (eicosapentaenoic and docosahexaenoic) in patients with cystic fibrosis. J. Parenter. Enteral Nutr. 27 (2003) 52-57
59. Freedman S.D., Blanco P.G., Zaman M.M., et al. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N. Engl. J. Med. 350 (2004) 560-569
60. Gronowitz E., Mellstrom D., and Strandvik B. Serum phospholipids fatty acid pattern is associated with bone mineral density in children, but not adults, with cystic fibrosis. Br. J. Nutr. 95 (2006) 1159-1165
61. Olveira G., Dorado A., Olveira C., et al. Serum phospholipids fatty acid profile and dietary intake in an adult Mediterranean population with cystic fibrosis. Br. J. Nutr. 96 (2006) 343-349
62. Arab L., and Akbar J. Biomarkers and the measurement of fatty acids. Public Health Nutr. 5 (2002) 865-871
63. Rivers J.P., and Hassam A.G. Defective essential-fatty-acid metabolism in cystic fibrosis. Lancet 306 (1975) 642-643
64. Peretti N., Marcil V., Drouin E., and Levy E. Mechanisms of lipid malabsorption in cystic fibrosis: the impact of essential fatty acids deficiency. Nutr. Metab. 2 (2005) 11
65. Strandvik B., Svensson E., and Seyberth H.W. Prostanoid biosynthesis in patients with cystic fibrosis. Prostaglandins Leukot. Essent Fatty Acids 55 (1996) 419-425
66. Prescott Jr. W.A., and Johnson C.E. Antiinflammatory therapies for cystic fibrosis: past, present, and future. Pharmacotherapy 25 (2005) 555-573
67. van Egmond A.W., Kosorok M.R., Koscik R., Laxova A., and Farrell P.M. Effect of linoleic acid intake on growth of infants with cystic fibrosis. Am. J. Clin. Nutr. 63 (1996) 746-752
68. Freedman S.D., Katz M.H., Parker E.M., Laposata M., Urman M.Y., and Alvarez J.G. A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr (-/-) mice. Proc. Natl. Acad Sci. U. S. A. 96 (1999) 13995-40000
69. 4. Lancet 342 (1993) 465-469
70. 4 in patients with cystic fibrosis. Pediatr. Pulmonol. 18 (1994) 211-217
71. Henderson Jr. W.R., Astley S.J., McCready M.M., et al. Oral absorption of omega-3 fatty acids in patients with cystic fibrosis who have pancreatic insufficiency and in healthy control subjects. J. Pediatr. 124 (1994) 400-408
72. Katz D.P., Manner T., Furst P., and Askanazi J. The use of an intravenous fish oil emulsion enriched with omega-3 fatty acids in patients with cystic fibrosis. Nutrition 12 (1996) 334-339
73. Thies N.H. The effect of 12 months' treatment with eicosapentaenoic acid in five children with cystic fibrosis. J. Paediatr. Child Health 33 (1997) 349-351
74. Jumpsen J.A., Brown N.E., Thomson A.B., et al. Fatty acids in blood and intestine following docosahexaenoic acid supplementation in adults with cystic fibrosis. J. Cyst. Fibros 5 (2006) 77-84
75. LlyodStill J.D., Powers C.A., Hoffman D.R., et al. Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: a randomized controlled study. Nutrition 22 (2006) 36-46
76. Panchaud A., Sauty A., Kernen Y., et al. Biological effects of a dietary omega-3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: a randomized, crossover placebo-controlled trial. Clin. Nutr. 25 (2006) 418-427
77. Beckless Willson N., Elliott T.M., and Everard M.L. Omega-3 fatty acids (from fish oils) for cystic fibrosis. Cochrane Database Syst. Rev. 3 (2002) (CD002201)
78. Strandvik B. Fatty acid metabolism in cystic fibrosis. N. Engl. J. Med. 350 (2004) 605-606
79. Palozza P., Sgarlata E., Luberto C., et al. n-3 fatty acids induce oxidative modifications in human erythrocytes depending on dose and duration of dietary supplementation. Am. J. Clin. Nutr. 64 (1996) 297-304
80. Barber M.D., and Fearon K.C. Tolerance and incorporation of a high-dose eicosapentaenoic acid diester emulsion by patients with pancreatic cancer cachexia. Lipids 36 (2001) 347-351
81. Pacetti D., Malavolta M., Bocci F., Boselli E., and Frega N.G. High-performance liquid chromatography/electrospray ionization ion-trap tandem mass spectrometric analysis and quantification of phosphatidylcholine molecular species in the serum of cystic fibrosis subjects supplemented with docosahexaenoic acid. Rapid. Commun. Mass Spectrom 18 (2004) 2395-2400
82. Fave G., Coste T.C., and Armand M. Physicochemical properties of lipids: new strategies to manage fatty acid bioavailability. Cell Mol. Biol. 50 (2004) 815-831
83. Van Biervliet S., Van Biervliet J.P., Robberecht E., and Christophe A. Docosahexaenoic acid trials in cystic fibrosis: a review of the rationale behind the clinical trials. J. Cyst. Fibros 4 (2005) 27-34
84. Cawood A.L., Carroll M.P., Wootton S.A., and Calder P.C. Is there a case for n-3 fatty acid supplementation in cystic fibrosis?. Curr. Opin. Clin. Nutr. Metab. Care 8 (2005) 153-159
85. Poppitt S.D., Kilmartin P., Butler P., and Keogh G.F. Assessment of erythrocyte phospholipid fatty acid composition as a biomarker for dietary MUFA, PUFA or saturated fatty acid intake in a controlled cross-over intervention trial. Lipids Health Dis. 4 (2005) 30
86. Cao J., Schwichtenberg K.A., Hanson N.Q., and Tsai M.Y. Incorporation and clearance of omega-3 fatty acids in erythrocyte membranes and plasma phospholipids. Clin. Chem. 52 (2006) 2265-2272